ITCI
ITCI Real Time Price USDRecent trades of ITCI by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ITCI's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$70,000 Apr 21, 2025 Issue: Medicare/Medicaid Taxation/Internal Revenue Code
-
$40,000 Jan 17, 2025 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$50,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$50,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$70,000 Apr 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$40,000 Jan 22, 2024 Issue: Health Issues
-
$10,000 Oct 19, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$40,000 Jul 17, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$50,000 Jan 19, 2023 Issue: Health Issues Medicare/Medicaid
-
$15,000 Nov 21, 2022 Issue: Medicare/Medicaid Health Issues
-
$20,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$10,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$20,000 Feb 28, 2005 Issue: Budget/Appropriations
-
$20,000 Aug 20, 2004 Issue: Budget/Appropriations
Estimated quarterly lobbying spending
ITCI Revenue by Segment or Geography
New patents grants
-
Patent Title: Organic compounds Apr. 08, 2025
-
Patent Title: Transmucosal methods for treating psychiatric and neurological conditions Apr. 08, 2025
-
Patent Title: Pharmaceutical compositions comprising 4-((6br, 10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h,7h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one for treating central nervous system disorders Apr. 01, 2025
-
Patent Title: Pharmaceutical compositions comprising 4-((6br, 10as)-3-methyl-2,3,6b,9,10, 10a-hexahydro-1h,7h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-ol for treating central nervous system disorders Mar. 04, 2025
-
Patent Title: Lumateperone bis-tosylate salts and crystals and methods for manufacture thereof Jan. 14, 2025
-
Patent Title: Organic compounds Jan. 14, 2025
-
Patent Title: Organic compound Jan. 14, 2025
-
Patent Title: Uses Jan. 14, 2025
-
Patent Title: Compounds Dec. 31, 2024
-
Patent Title: Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs Dec. 24, 2024
-
Patent Title: Compositions and methods Nov. 19, 2024
-
Patent Title: Process for preparing 1-(4-fluorophenyl)-4-((6br, 10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)butan-1-one Nov. 12, 2024
-
Patent Title: Pharmaceutical capsules comprising lumateperone mono-tosylate Oct. 29, 2024
-
Patent Title: Pharmaceutical compositions comprising 4-((6br,10as)-3-methyl2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7h)-yl)-1-(4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders Oct. 22, 2024
-
Patent Title: Methods Sep. 17, 2024
-
Patent Title: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Aug. 27, 2024
-
Patent Title: Methods Jul. 02, 2024
-
Patent Title: Methods of treating acute depression and/or acute anxiety May. 14, 2024
-
Patent Title: Compounds and methods Apr. 16, 2024
-
Patent Title: Methods Apr. 16, 2024
-
Patent Title: Amorphous solid dispersions Jan. 16, 2024
-
Patent Title: Organic compounds Dec. 19, 2023
-
Patent Title: Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine a Dec. 12, 2023
-
Patent Title: Amorphous solid dispersions Nov. 28, 2023
-
Patent Title: Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate Nov. 07, 2023
-
Patent Title: Transmucosal methods for treating psychiatric and neurological conditions Nov. 07, 2023
-
Patent Title: Organic compounds Oct. 03, 2023
-
Patent Title: Uses Sep. 19, 2023
-
Patent Title: 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)-1-(4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders Sep. 12, 2023
-
Patent Title: Organic compounds Aug. 15, 2023
-
Patent Title: Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Jul. 04, 2023
-
Patent Title: Pharmaceutical compositions comprising 4-(6br,10as)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1h, 7h-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8yl)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system Jun. 20, 2023
-
Patent Title: Organic compounds Jan. 24, 2023
-
Patent Title: Uses Nov. 22, 2022
-
Patent Title: Organic compounds Nov. 08, 2022
-
Patent Title: Pde1 inhibitors for ophthalmic disorders Oct. 11, 2022
-
Patent Title: Substituted heterocycle fused gamma-carbolines synthesis Sep. 27, 2022
-
Patent Title: Salts and crystals Sep. 13, 2022
-
Patent Title: Organic compounds Aug. 30, 2022
-
Patent Title: Hydrochloric acid salt of (6br,10as)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline Aug. 09, 2022
-
Patent Title: Organic compounds Jul. 05, 2022
-
Patent Title: Amorphous solid dispersions May. 17, 2022
-
Patent Title: Amorphous solid dispersions Apr. 26, 2022
-
Patent Title: Uses Apr. 05, 2022
-
Patent Title: Methods and compositions for sleep disorders and other disorders Dec. 07, 2021
-
Patent Title: 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms Nov. 23, 2021
-
Patent Title: Combinations of pde1 inhibitors and nep inhibitors Nov. 09, 2021
-
Patent Title: Compositions and methods Sep. 21, 2021
-
Patent Title: Organic compounds Aug. 24, 2021
-
Patent Title: Preparation of certain substituted 1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof Jul. 20, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ITCI
Recent picks made for ITCI stock on CNBC
ETFs with the largest estimated holdings in ITCI
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ITCI stock a Buy, Sell, or Hold?
- What is the price target for $ITCI stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ITCI stock?
- Who owns the most shares of $ITCI stock?
- What funds own $ITCI stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ITCI Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.